This article discusses chemical strategies for detecting and eliminating senescent cells, which are cells that have stopped dividing and can contribute to aging and disease. Senescent cells accumulate in various tissues and are linked to conditions such as cancer, fibrosis, and aging. Detecting and eliminating these cells is challenging, but recent advances in chemical probes, nanoparticles, and prodrugs offer promising solutions. The authors describe the development of new chemical approaches for detecting and eliminating senescent cells. These include two-photon probes, fluorogenic probes, and nanoparticles that can be activated by the enzyme β-galactosidase, which is overexpressed in senescent cells. These tools allow for in vivo detection of senescence and can be used to monitor the effectiveness of therapies aimed at eliminating senescent cells. In addition, the article highlights the development of new therapeutic agents that can selectively target and eliminate senescent cells. These include nanoparticles and prodrugs that are activated by β-galactosidase, which increases their selectivity and reduces off-target toxicity. These strategies have been tested in various preclinical models, including cancer, fibrosis, and drug-induced cardiotoxicity. The authors also discuss the potential of these chemical strategies for future applications in clinical settings. By improving the specificity and safety of senolytic therapies, these approaches could lead to more effective treatments for age-related diseases and cancer. The use of nanoparticles and prodrugs offers a promising avenue for targeted therapy, reducing side effects and enhancing the effectiveness of existing drugs. Overall, the research emphasizes the importance of developing new chemical strategies to detect and eliminate senescent cells, which could significantly impact the treatment of age-related diseases.This article discusses chemical strategies for detecting and eliminating senescent cells, which are cells that have stopped dividing and can contribute to aging and disease. Senescent cells accumulate in various tissues and are linked to conditions such as cancer, fibrosis, and aging. Detecting and eliminating these cells is challenging, but recent advances in chemical probes, nanoparticles, and prodrugs offer promising solutions. The authors describe the development of new chemical approaches for detecting and eliminating senescent cells. These include two-photon probes, fluorogenic probes, and nanoparticles that can be activated by the enzyme β-galactosidase, which is overexpressed in senescent cells. These tools allow for in vivo detection of senescence and can be used to monitor the effectiveness of therapies aimed at eliminating senescent cells. In addition, the article highlights the development of new therapeutic agents that can selectively target and eliminate senescent cells. These include nanoparticles and prodrugs that are activated by β-galactosidase, which increases their selectivity and reduces off-target toxicity. These strategies have been tested in various preclinical models, including cancer, fibrosis, and drug-induced cardiotoxicity. The authors also discuss the potential of these chemical strategies for future applications in clinical settings. By improving the specificity and safety of senolytic therapies, these approaches could lead to more effective treatments for age-related diseases and cancer. The use of nanoparticles and prodrugs offers a promising avenue for targeted therapy, reducing side effects and enhancing the effectiveness of existing drugs. Overall, the research emphasizes the importance of developing new chemical strategies to detect and eliminate senescent cells, which could significantly impact the treatment of age-related diseases.